Amnion-derived multipotent progenitor cells support allograft tolerance induction

K. Anam, Y. Lazdun, P. M. Davis, R. A. Banas, E. A. Elster, T. A. Davis*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Donor-specific immunological tolerance using high doses of bone marrow cells (BMCs) has been demonstrated in mixed chimerism-based tolerance induction protocols; however, the development of graft versus host disease remains a risk. Here, we demonstrate that the co-infusion of limited numbers of donor unfractionated BMCs with human amnion-derived multipotent progenitor cells (AMPs) 7 days post-allograft transplantation facilitates macrochimerism induction and graft tolerance in a mouse skin transplantation model. AMPs + BMCs co-infusion with minimal conditioning led to stable, mixed, multilineage lymphoid and myeloid macrochimerism, deletion of donor-reactive T cells, expansion of CD4+CD25+Foxp3+ regulatory T cells (Tregs) and long-term allograft survival (>300 days). Based on these findings, we speculate that AMPs maybe a pro-tolerogenic cellular therapeutic that could have clinical efficacy for both solid organ and hematopoietic stem cell transplant applications. The authors demonstrate that a subset of human amnion epithelial cells can promote engraftment of limiting numbers of donor bone marrow leading to stable multilineage mixed-chimerism and skin allograft tolerance.

Original languageEnglish
Pages (from-to)1416-1428
Number of pages13
JournalAmerican Journal of Transplantation
Issue number6
StatePublished - Jun 2013
Externally publishedYes


  • Allogeneic transplantation
  • T regulatory cells
  • amnion-derived multipotent progenitor cells
  • bone marrow
  • chimerism
  • tolerance induction


Dive into the research topics of 'Amnion-derived multipotent progenitor cells support allograft tolerance induction'. Together they form a unique fingerprint.

Cite this